^
BIOMARKER:

FGFR1 expression

i
Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
Entrez ID:
4d
Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors. (PubMed, J Cancer Res Clin Oncol)
FGFR1 hotspot mutations are the fifth most prevailing alteration in LGG/MNGT. Performing FGFR1 sequencing analysis in driver-unknown low-grade brain tumors could yield up to 12% FGFR1 N546/K656 mutant cases.
Journal
|
BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR1 (Fibroblast growth factor receptor 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NF1 (Neurofibromin 1) • KIAA1549
|
BRAF mutation • FGFR1 mutation • BRAF fusion • FGFR1 expression • FGFR1 fusion
6d
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. (PubMed, Oncoimmunology)
Notably, FGFR-TKIs augmented antitumor effects of FGFR1-reactive T cells against human HNSCC cells. These results indicate that the combination of FGFR-TKIs with immunotherapy, such as an FGFR1-targeting peptide vaccine or immune checkpoint inhibitor, could be a novel and robust immunologic approach for treating patients with FGFR1-expressing cancer cells.
Journal • IO biomarker
|
FGFR1 (Fibroblast growth factor receptor 1) • CD4 (CD4 Molecule)
|
FGFR1 expression • MHC-II expression
11d
Crosstalk of FGFR1 signaling and choline metabolism promotes cell proliferation and survival in prostate cancer cells. (PubMed, Int J Cancer)
We also first time demonstrated that FGFR1 formed complex with CHKA, suggesting that FGFR1 regulated CHKA at the posttranslational level. Together with the previous report that ectopic FGFR1 contributes to PCa progression and metastasis, our results here unravel a novel mechanism by which FGFR1 promotes PCa progression by dysregulating choline metabolism, and that the crosstalk between FGFR1-choline metabolism can be a potential target for managing PCa progression.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
19d
Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. (PubMed, Front Endocrinol (Lausanne))
Collectively, our study supports a role of FGF pathways in malignant adrenocortical tumors. Quantification of FGF receptors may enable a stratification of ACC for the use of FGFR inhibitors in future clinical trials.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR1 overexpression • FGFR1 expression
20d
FGF signalling facilitates cervical cancer progression. (PubMed, FEBS J)
Importantly, 2D and 3D cell cultures demonstrated that FGFR activation can facilitate cell functions correlated with invasive disease. Collectively, this work supports an association between FGFR signalling and cervical cancer progression, laying the foundations for the development of therapeutic approaches targeting FGFR in this disease.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4) • FGF (Fibroblast Growth Factor) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR1 expression
1m
C1632 suppresses the migration and proliferation of non-small-cell lung cancer cells involving LIN28 and FGFR1 pathway. (PubMed, J Cell Mol Med)
In addition, C1632 also displayed the capacity to inhibit the growth of A549R xenograft tumours in mice. Altogether, these findings reveal the potential of C1632 as a promising anti-NSCLC agent, especially for chemotherapy-resistant NSCLC treatment.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • MMP9 (Matrix metallopeptidase 9)
|
FGFR1 expression
1m
Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent. (PubMed, Front Pharmacol)
Essentially, the development of new effective FGFR1 binders that comprise the naturally occurring FGFR-recognition peptides and Fc region ensuring high plasma stability, and long bloodstream circulation is an interesting strategy expanding targeted anticancer agents' portfolio. Furthermore, identifying peptides effectively binding the receptor from sequences of its ligands is not limited to FGFRs and is an approach versatile enough to be a basis for a new peptide/peptibodies development strategy.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGF4 (Fibroblast growth factor 4)
|
FGFR1 expression • FGFR1 fusion
2ms
ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY. (PubMed, Cell Death Dis)
Furthermore, the combination of FGFR1 inhibitor PD173074 with ACLY inhibitor ETC-1002 markedly suppressed ONECUT2-mediated HCC metastasis. In summary, ONECUT2 was a potential prognostic biomarker in HCC and targeting this oncogenic signaling pathway may provide an efficient therapeutic strategy against HCC metastasis.
Journal
|
FGF2 (Fibroblast Growth Factor 2)
|
FGFR1 expression
|
Nexletol (bempedoic acid)
2ms
Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. (PubMed, Eur Urol Oncol)
FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
2ms
Knockdown of lncRNA NEAT1 suppresses proliferation and migration, and induces apoptosis of cervical cancer cells by regulating the miR‑377/FGFR1 axis. (PubMed, Mol Med Rep)
Moreover, a dual luciferase reporter assay confirmed that FGFR1 was a direct target of miR‑377. In conclusion, suppression of NEAT1 inhibited cell viability and migration, and promoted apoptosis of CC cells, and these effects were achieved through regulation of the miR‑377/FGFR1 axis.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
2ms
Elucidating the role of co-occurring mutations in FGFR1-driven pediatric low-grade glioma (SNO 2021)
Treatment with an FGFR inhibitor (Infigratinib) showed reduced drug response in double mutant cells compared to hot-spot mutated FGFR1 alone. This was associated with less reduction of phosphorylation of ERK and S6 in the double mutant cells upon treatment. In conclusion, the presence of a second alteration influences proliferation and drug response in models of FGFR1 -mutated pLGG, potentially by modulating MAPK and mTOR signaling.
Clinical
|
BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR1 (Fibroblast growth factor receptor 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)
|
FGFR1 mutation • MTOR mutation • FGFR1 expression
|
Truseltiq (infigratinib)
2ms
Molecular Characterization of Peritoneal Involvement in Primary Colon and Ovary Neoplasm: The Possible Clinical Meaning of the P2X7 Receptor-Inflammasome Complex. (PubMed, Eur Surg Res)
We show here that rarely measured molecules seem to specifically characterize omental carcinomatosis of CC or EOC, while more common inflammatory agents like TNFα, TGFβ, or MCP-1 do not; the P2X7R-NLRP3 complex marks omental and peritoneal carcinosis and is related to circulating white blood cells and MCP-1, involved in monocyte-macrophage tissue infiltration; increased TGFβ and FGFR1 characterize the tumoral dissemination.
Clinical • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • CD68 (CD68 Molecule) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
FGFR1 expression
2ms
Platelet Transcriptome Yields Progressive Markers in Chronic Myeloproliferative Neoplasms and Identifies Putative Targets of Therapy (ASH 2021)
Also, focusing on the JAK-inhibitor ruxolitinib/RUX-specific signatures, we not only confirm previous observations on its anti-inflammatory and immunosuppressive effects ( e.g. downregulation in our RUX-treated cohort of IL1RAP, CXCR5, CPNE3, ILF3 ) but also identify new gene clusters responsive to RUX – e.g. inhibition of type I interferon (e.g. IFIT1, IFIT2, IFI6 ), chromatin regulation ( HIST2H3A/C, HIST1H2BK, H2AFY, SMARCA4, SMARCC2 ), epigenetic methylation in mitochondrial genes ( ATP6, ATP8, ND1-6 and NDUFA5 ), and other proliferation, and proteostasis-associated markers as putative targets for MPN-directed therapy...Together, our platelet transcriptome snapshot of chronic MPNs demonstrates a methodological avenue for disease risk stratification and progression beyond genetic data alone, with potential utility in a wide range of age-related disorders. Part of the work contributing to this abstract has been posted as a preprint at this link: https://www.biorxiv.org/content/10.1101/2021.03.12.435190v2
FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • CCND1 (Cyclin D1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CD34 (CD34 molecule) • CCNA2 (Cyclin A2) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • CCNB2 (Cyclin B2) • IFI27 (Interferon Alpha Inducible Protein 27) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7) • MCT1 (SLC16A1) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1)
|
FGFR1 expression
|
Jakafi oral (ruxolitinib)
3ms
Targeted Inhibition of Fibroblast Growth Factor Receptor 1-GLI Through AZD4547 and GANT61 Modulates Breast Cancer Progression. (PubMed, Front Cell Dev Biol)
A strong positive feedback mechanism between FGFR1-GLI1 axis was observed, which significantly increased cell proliferation and metastasis. Targeting FGFR1-GLI1 simultaneously will significantly improve the prognosis of breast cancer in patients.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • GLI1 (GLI Family Zinc Finger 1)
|
FGFR1 expression
|
ABSK091
3ms
Oligodendrocyte-Specific Deletion of FGFR1 Reduces Cerebellar Inflammation and Neurodegeneration in MOG-Induced EAE. (PubMed, Int J Mol Sci)
Conditional deletion of FGFR1 in oligodendrocytes (Fgfr1) was achieved by tamoxifen application, EAE was induced using the MOG peptide...The FGF/FGFR signaling protein pAkt, BDNF, and TrkB were increased in Fgfr1 mice. These data suggest that cell-specific deletion of FGFR1 in oligodendrocytes has anti-inflammatory and neuroprotective effects in the cerebellum in the EAE disease model of MS.
Journal
|
NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR1 (Fibroblast growth factor receptor 1) • IL6 (Interleukin 6) • FGF2 (Fibroblast Growth Factor 2) • CD200 (CD200 Molecule) • IL1B (Interleukin 1, beta)
|
FGFR1 expression
|
tamoxifen
3ms
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations (SABCS 2021)
Futibatinib had single agent activity of selected breast cancer PDX models. FGFR2 activating mutations and amplification may represent rare but promising therapeutic targets to FGFR inhibition.
Clinical • Preclinical
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • BICC1 (BicC Family RNA Binding Protein 1)
|
FGFR2 mutation • FGFR2 amplification • FGFR2 fusion • FGFR2-BICC1 fusion • FGFR1 expression • FGFR2b expression • FGFR3 Y375C • FGFR4 expression • FGFR2 Y375C • FGFR2 expression
|
futibatinib (TAS 120)
4ms
High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer. (PubMed, Clin Cancer Res)
Tailored therapy with FGFRi in molecularly-selected metastatic BC based on high FGFR1-4 mRNA levels warrants prospective validation in luminal BC CDK4/6i-resistant patients and in TNBC patients without targeted therapeutic options.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
FGFR1 amplification • FGFR1 expression • FGFR3 amplification
4ms
Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling. (PubMed, Endocr J)
Through using MET specific inhibitor PHA665752, we found that circ_0079558 overexpression enhanced the malignant behaviors of PTC cells through activating MET/AKT pathway...Through xenograft tumor model, we found that circ_0079558 silencing restrained xenograft tumor growth in vivo. In conclusion, circ_0079558 facilitated the proliferation and motility whereas inhibited the apoptosis of PTC cells largely through mediating miR-26b-5p/MET/AKT signaling.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1)
|
MET overexpression • MET expression • FGFR1 expression
|
PHA665752
4ms
Lower melanoma pulmonary metastatic burden in obese mice: role of FGF-21. (PubMed, Melanoma Res)
FGF-21 reduced melanoma viability in LPS-stimulated macrophages. Altogether, these findings suggest that higher amounts of FGF-21 are able to counterbalance the proinflammatory effects associated with obesity, protecting the lungs from melanoma metastization.
Preclinical • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGF21 (Fibroblast Growth Factor 21)
|
FGFR1 expression
4ms
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. (PubMed, Front Endocrinol (Lausanne))
Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising...FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR1 (Fibroblast growth factor receptor 1)
|
PD-L1 expression • FGFR1 expression • FGFR expression
|
Keytruda (pembrolizumab) • lenvatinib
5ms
Effect of miRNA-136-targeted regulation of FGFR1 on proliferation and apoptosis of triple-negative breast cancer cells. (PubMed, Am J Transl Res)
miRNA-136 shows a very low expression level in TNBC cells. Transfection with miRNA-136 can significantly inhibit the proliferation of TNBC cells by external transfection, and has little effect on cell apoptosis. This may be related to miRNA-mediated changes in FGFR1 protein expression.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • MIR136 (MicroRNA 136)
|
FGFR1 expression
6ms
[VIRTUAL] FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC). (ERS 2021)
Research in progress. Co-funded by the National Centre for Research and Development and CelonPharma within the Strategmed programme.
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR1 (Fibroblast growth factor receptor 1) • NRG1 (Neuregulin 1)
|
NTRK1 fusion • NTRK3 fusion • EGFR expression • FGFR1 amplification • ALK fusion • ROS1 fusion • NRG1 fusion • FGFR1 expression • FGFR1 fusion
|
Archer® FusionPlex® Lung Kit
6ms
Effect of miR-133b on progression and cisplatin resistance of triple-negative breast cancer through FGFR1-Wnt-β-catenin axis. (PubMed, Am J Transl Res)
To sum up, miR-133b can inhibit the growth and DDP resistance of TNBC cells by targeting FGFR1 and inactivating the Wnt-β-catenin pathway.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
FGFR1 expression
|
cisplatin
6ms
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells. (PubMed, NPJ Precis Oncol)
Using spectrometry-based proteomics, we identified increased fibroblast growth factor receptor 1 (FGFR1) expression and Akt activation across erlotinib, gefitinib, and osimertinib EGFR-TKI-resistant cell line models. Further, increased FGFR1 expression was associated with significantly lower PFS in EGFR-TKI-treated NSCLC patients, and increased FGFR1 were demonstrated in a few post- vs. pre-EGFR-TKI treatment clinical biopsies. The superior therapeutic benefit of combining FGFR and Akt inhibitors provide the rationale for clinical trials of this strategy.
Journal
|
EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1)
|
EGFR overexpression • FGFR1 overexpression • FGFR1 expression
|
erlotinib • Tagrisso (osimertinib) • gefitinib
6ms
Circ-TFF1 Facilitates Breast Cancer Development via Regulation of miR-338-3p/FGFR1 Axis. (PubMed, Biochem Genet)
Additionally, circ-TFF1 knockdown hampered tumorigenesis in vivo. Circ-TFF1 knockdown suppressed BC progression by regulating miR-338-3p/FGFR1 axis, providing a promising therapeutic target for BC.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • TFF1 (Trefoil Factor 1)
|
FGFR1 expression
7ms
FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis. (PubMed, Oncogene)
BLU9931 inhibited FGFR4 and attenuated its oncogenic effects in GBC cell line...Co-expression of FGF19 and FGFR4 was a sensitive and unfavorable prognostic marker. GBC cells secreted FGF19 and facilitated progression by activating FGFR4 with bile as a potential carrier in an autocrine pathway.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • EGR1 (Early Growth Response 1)
|
FGFR1 expression • FGF19 expression
|
BLU 9931
7ms
Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint inhibitor therapy. (PubMed, Urology)
Assessment of FGFR mRNA expression identified a high-risk subgroup of patients with mUCa. These patients showing overexpression of FGFR3 mRNA were found to have unfavorable DSS after CPI treatment. Using this approach may be suitable for identifying a patient population with poor response to CPI treatment, which may benefit from early FGFR inhibition.
Journal • Checkpoint inhibition
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 fusion • FGFR3 mutation • FGFR3 overexpression • FGFR3 fusion • FGFR1 expression • FGFR2b expression • FGFR3 expression • FGF3 overexpression • FGFR2 expression
7ms
LncRNA PVT1 Facilitates Proliferation, Migration and Invasion of NSCLC Cells via miR-551b/FGFR1 Axis. (PubMed, Onco Targets Ther)
Besides, PVT1 could increase FGFR1 expression by repressing miR-551b expression. PVT1 promotes the proliferation, migration and invasion of NSCLC cells by indirectly mediating FGFR1 via targeting miR-551b.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • PVT1 (Pvt1 Oncogene)
|
FGFR1 expression
8ms
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. (PubMed, Cells)
FGFR directly interacts with cell adhesion molecules (CAMs) and extracellular matrix (ECM) proteins, contributing to invasive and migratory properties of cancer cells, whereas interactions with other receptor tyrosine kinases (RTKs) regulate angiogenic, resistance to therapy, and metastatic potential of cancer cells. The diversity in FGFR signaling partners supports a role for FGFR signaling in cancer, independent of genetic aberration.
Review • Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 mutation • FGFR1 expression
8ms
Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes. (PubMed, Cells)
FGFR inhibition was achieved by application of the multi-kinase-inhibitor dovitinib and the FGFR1/2/3-inhibitor AZD4547. Decreased phosphorylation of ERK and Akt is associated with an upregulation of BDNF/TrkB signaling, which may be responsible for the increased production of myelin proteins. Furthermore, these data suggest that application of FGFR inhibitors may have the potential to promote remyelination in the CNS.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 expression
|
ABSK091 • dovitinib (TKI258)
8ms
Targeting fibroblast growth factor receptors to combat aggressive ependymoma. (PubMed, Acta Neuropathol)
Finally, we gain the first clinical evidence for the activity of the FGFR inhibitor nintedanib in the treatment of a patient with recurrent ST-RELA. Together, these preclinical and clinical data suggest FGFR inhibition as a novel and feasible approach to combat aggressive EPN.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF2 (Fibroblast Growth Factor 2) • RELA (RELA Proto-Oncogene)
|
FGFR3 fusion • FGFR1 expression
|
nintedanib
8ms
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer. (PubMed, Clin Cancer Res)
These data suggest nuclear FGFR1 contributes to endocrine resistance by modulating gene transcription in ER+ breast cancer. Nuclear FGFR1 activity was unaffected by FGFR TKIs, thus supporting the development of treatment strategies to inhibit nuclear FGFR1 in ER+/FGFR1 overexpressing breast cancer.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FOXA1 (Forkhead Box A1)
|
FGFR1 amplification • FGFR1 overexpression • FGFR1 expression
|
Balversa (erdafitinib) • fulvestrant • letrozole
8ms
Prognostic value of FGFR1 expression and amplification in patients with HNSCC: A systematic review and meta-analysis. (PubMed, PLoS One)
Subgroup analysis stratified by molecular abnormalities, such as overexpression or amplification showed the similar results. The present study demonstrated that HNSCC patients with FGFR1 overexpression and amplification were more likely to exhibit poorer survival.
Retrospective data • Review • Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 amplification • FGFR1 overexpression • FGFR1 expression
8ms
FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. (PubMed, Eur J Cancer)
Finally, NSCLC PDX models demonstrating FGFR1 amplification and FGFR1 protein overexpression were sensitive to M6123. The unique molecular and immune features of tumours with high FGFR1 expression provide a rationale to stratify patients in future clinical trials of FGFR1 pathway-targeting agents.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
PD-L1 expression • FGFR1 amplification • FGFR1 overexpression • FGFR1 expression
|
M6123
9ms
[VIRTUAL] KEAP1 mutations in squamous cell lung cancer. (ASCO 2021)
KEAP1 mutations occur commonly in SqCC patients and do not impact the efficacy of ICI in terms of OS . To identify prognostic markers for response to ICI further research is needed.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • PTEN (Phosphatase and tensin homolog) • FGFR1 (Fibroblast growth factor receptor 1) • KEAP1 (Kelch Like ECH Associated Protein 1)
|
PD-L1 expression • TP53 mutation • KRAS mutation • MET amplification • PTEN mutation • FGFR1 amplification • KEAP1 mutation • FGFR1 expression
9ms
[VIRTUAL] Association of FGFR alterations with FGFR 1-4 gene expression in TUR biopsies and matched NMP22 urine levels in early bladder cancer of the prospective real world clinico-pathological register trial: BRIDGister. (ASCO 2021)
In early bladder cancer FGFR3 alterations are tightly associated with a characteristic FGFR mRNA signature . Mutation/Fusion of FGFR3 results in high FGFR3 but low FGFR1 and FGFR4 mRNA expression, which might be i.a . relevant for the response to FGFR inhibition and important to predict outcome of FGFR inhibitors .
Clinical • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4) • KRT5 (Keratin 5) • KRT20 (Keratin 20)
|
FGFR3 mutation • FGFR3 fusion • FGFR1 expression • FGFR1 fusion • FGFR3 expression • FGFR4 expression
9ms
[VIRTUAL] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study. (ASCO 2021)
First-line treatment with the RP2D of R+A achieved favorable clinical efficacy and tolerability in pts with cisplatin-ineligible, metastatic UC characterized by high FGFR1/3 mRNA expression and generally low/negative PD-L1 expression . Encouraging efficacy was observed regardless of PD-L1 expression or FGFR3 mutation status, warranting future investigation.
Combination therapy • P1/2 data • Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 negative • FGFR3 mutation • FGFR3 overexpression • FGFR fusion • FGFR1 expression • FGFR3 expression • FGF3 overexpression
|
cisplatin • Tecentriq (atezolizumab) • rogaratinib (BAY 1163877)
9ms
Fibroblast growth factor receptor 1 protein (FGFR1) as potential prognostic and predictive marker in patients with luminal B breast cancers overexpressing human epidermal receptor 2 protein (HER2). (PubMed, Indian J Pathol Microbiol)
FGFR1 expression affect luminal B patients survival with poor outcome. FGFR1 expression may serve as a prognostic and predictive factor in luminal breast cancers, it can also be considered as a potential therapeutic target in luminal B cases.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • FGFR1 (Fibroblast growth factor receptor 1)
|
HER-2 overexpression • FGFR1 expression
9ms
Altered immunolocalization of FGF23 in murine femora metastasized with human breast carcinoma MDA-MB-231 cells. (PubMed, J Bone Miner Metab)
MDA-MB-231 cells revealed intense FGF23 reactivity in metastasized lesions, whereas MDA-MB-231 cells cultured in vitro or when injected into the mammary glands (without bone metastasis) showed weak FGF23 immunoreactivity. Although the bone-metastasized MDA-MB-231 cells abundantly synthesized FGF23, osteocytes adjacent to the FGF23-immunopositive tumors, unlike intact osteocytes, showed no FGF23. Despite significantly elevated serum FGF23 levels in bone-metastasized mice, there was no significant decrease in the serum Pi concentration when compared with the intact mice and mice with a mass of MDA-MB-231 cells in mammary glands. The metastasized femora showed increased expression and FGFR1 immunoreactivity in fibroblastic stromal cells, whereas femora of control mice showed no obvious FGFR1 immunoreactivity. Taken together, it seems likely that MDA-MB-231 cells synthesize FGF23 when metastasized to a bone, and thus affect FGFR1-positive stromal cells in the metastasized tumor nest in a paracrine manner.
Preclinical • Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
9ms
Moxibustion inhibits growth of tumor by down-regulating expression of FGFR1 and VEGFR2 in mice with sarcoma (PubMed, Zhen Ci Yan Jiu)
Moxibustion can inhibit the growth of tumor in mice with sarcoma, which may be related to its function in reducing the expression of FGFR1 and VEGFR2 to inhibit angiogenesis.
Preclinical • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • KDR (Kinase insert domain receptor)
|
FGFR1 expression • KDR expression • VEGFA expression
10ms
Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells. (PubMed, J Chemother)
Furthermore, expression levels of osteosarcoma related genes, OPG, ERα, ERβ, IL15, BMP2 and BMP7, were found to have increased significantly. Biological activities of STA-9090 on Saos-2 cell line show its potential as a target specific drug to inhibit osteosarcoma and its metastasis.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • IL6 (Interleukin 6) • DKK1 (dickkopf WNT signaling pathway inhibitor 1) • SPARC (Secreted Protein Acidic And Cysteine Rich) • TGFB1 (Transforming Growth Factor Beta 1) • MMP2 (Matrix metallopeptidase 2)
|
FGFR1 expression
|
ganetespib (ADX-1612)
10ms
Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma. (PubMed, Am J Clin Exp Urol)
Expression of FGF2 and its receptors was found on the surface and in the cytoplasm of RCC primary tumor cells and needs following investigations.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR2 overexpression • FGFR1 expression • FGFR2b expression
10ms
FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression. (PubMed, Technol Cancer Res Treat)
In addition, knocking down FGFR1 inhibited cell proliferation and enhanced TAM sensitivity in TAM-resistant cells. In conclusion, we found that there was a significant negative correlation between FGFR1 and ER levels in ER breast cancers, high FGFR1 protein expression was associated with poor breast cancer prognosis, down-regulating FGFR1 could elevate ER expression and is associated with enhanced TAM sensitivity in ER breast cancers.
Journal
|
ER (Estrogen receptor) • FGFR1 (Fibroblast growth factor receptor 1)
|
ER positive • FGFR1 expression • ER expression
|
tamoxifen
10ms
SAKK 19/18: Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) (clinicaltrials.gov)
P2, N=15, Active, not recruiting, Swiss Group for Clinical Cancer Research | Recruiting --> Active, not recruiting | N=24 --> 15
Clinical • Enrollment closed • Enrollment change
|
CD4 (CD4 Molecule)
|
FGFR1 expression
|
rogaratinib (BAY 1163877)
10ms
Atractylenolide III predisposes miR-195-5p/FGFR1 signaling axis to exert tumor-suppressive functions in liver cancer. (PubMed, J Food Biochem)
ATL effectively repressed growth and induced apoptosis of human HCC cells through the upregulation of miR-195-5p to downregulate FGFR1 expression.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • MIR195 (MicroRNA 195)
|
FGFR1 expression
10ms
FGFR1 copy number in breast cancer: associations with proliferation, histopathological grade and molecular subtypes. (PubMed, J Clin Pathol)
Our results show that FGFR1 copy number increase is largely found among luminal subtypes of breast cancer, particularly luminal B (HER2). It is frequently accompanied by increased copy number of ZNF703. FGFR1 copy number increase is associated with high histopathological grade and high proliferation. However, we did not discover an association with prognosis.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
10ms
[VIRTUAL] Role of the FGFR1-KDM2B-EZH2 signaling axis in bone-marrow microenvironment mediated tumor survival & drug resistance in Mantle cell lymphoma (AACR 2021)
There is a high propensity towards development of drug resistance against treatment options presently available such as ibrutinib, a Bruton’s Tyrosine Kinase (BTK) inhibitor...KDM2B & EZH2 expression were lowered in FGFR1KD cells & expression of miR-101 was increased, along with decreased fold enrichment of KDM2B at the miR-101 promoter locus, indicating a decreased KDM2B-mediated repression of this negative regulator of EZH2, a possible reason for EZH2 down-regulation. These results indicate the vitality of FGFR1-KDM2B-EZH2 signaling axis in tumor progression & drug resistance, shedding light on mechanisms for BM microenvironment mediated tumor survival, paving way for identification of new druggable targets.
FGFR1 (Fibroblast growth factor receptor 1) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • IL6 (Interleukin 6)
|
FGFR1 expression • IL6 expression
|
ibrutinib
10ms
[VIRTUAL] TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS (AACR 2021)
Unlike ARIH2-WT, ectopic expression of ARIH2K441N or ARIH2R484I blocked FGFR1 ubiquitination and degradation, activating STAT5, AKT and ERK1/2 signaling, suggesting that TET2 loss leads to secondly hits, which activate proliferation/survival signaling. Taken together, our finding provides a rationale for enhancing TET2 function to block MDS-malignant transformation.
Preclinical
|
FGFR1 (Fibroblast growth factor receptor 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
|
TET2 mutation • FGFR1 expression • TET2 deletion
10ms
[VIRTUAL] Targeted genomic profiling revealed association between genetic aberrations of fibroblast factor receptor and unique clinical phenotypes in Chinese patients with intrahepatic cholangiocarcinoma (AACR 2021)
FGFRs rearrangement is associated with unique clinical phenotypes in ICC, with features of younger age at onset, female sex, serum HBsAb positivity, and tumoral CD10 expression and PD-L1 expression. Molecular testing for target therapy of FGFR inhibitor should be prioritized for patients with the relevant clinical phenotypes.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4) • Cancer antigen 19-9 • MME (Membrane metallo-endopeptidase)
|
PD-L1 expression • FGFR2 mutation • FGFR1 mutation • FGFR1 expression
11ms
Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. (PubMed, Int J Mol Sci)
Induction of oxidative stress is the main mechanism responsible for the therapeutic/pro-apoptotic effect exerted by both NSC12 and erdafitinib, with apoptosis being abolished by antioxidant treatments. Finally, reduction of c-Myc protein levels appears to strictly determine the onset of oxidative stress and the therapeutic response to FGF/FGFR inhibition, indicating c-Myc as a key downstream effector of FGF/FGFR signaling in FGF-dependent lung cancers.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
|
Balversa (erdafitinib)
11ms
Evaluation of FGFR1 as a diagnostic biomarker for ovarian cancer using TCGA and GEO datasets. (PubMed, PeerJ)
Our study examined existing TCGA and GEO datasets for novel factors associated with OC and identified FGFR1 as a potential diagnostic factor. Further investigation is warranted to characterize the role played by FGFR1 in OC.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
11ms
Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis. (PubMed, Aging (Albany NY))
Rescue experiments revealed that miR-15a-5p downregulation or FGFR1 restoration rescued the effects of CERS6-AS1 knockdown on the behaviors of PDAC cells. In conclusion, CERS6-AS1 promoted the oncogenicity of PDAC by serving as a competing endogenous RNA to sequester miR-15a-5p and increase FGFR1 expression, which highlights the potential of the CERS6-AS1/miR-15a-5p/FGFR1 pathway as an effective target for cancer therapy.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
1year
Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. (PubMed, Acta Neuropathol Commun)
Other challenges in need of clarification include malignant tumor progression of LEAT entities, seizure relapse in patients following bulk tumor resection and the controversial issue of associated focal cortical dysplasia as additional pathomechanism. In order to advance our understanding and promote reliable diagnostic work-up of LEAT, we recommend, therefore, international collaboration to achieve our goals.
Review • Journal
|
BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR1 (Fibroblast growth factor receptor 1) • CD34 (CD34 molecule) • PRKCA (Protein Kinase C Alpha)
|
BRAF V600E • BRAF V600 • FGFR1 mutation • FGFR1 expression
1year
Newly identified members of fibroblast growth factor receptor 1 splice variants engage in crosstalk with the AXL/AKT axis in salivary adenoid cystic carcinoma. (PubMed, Cancer Res)
Moreover, cell killing was increased by dual inhibition of AXL and FGFR1 in ACC cells. This study demonstrates that these previously undescribed FGFR1v cooperate with AXL and desensitize cells to FGFR1 inhibitor, which supports further investigation into combined FGFR1 and AXL inhibition as an effective ACC therapy.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • AXL (AXL Receptor Tyrosine Kinase) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 expression
1year
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. (PubMed, Clin Cancer Res)
Cabozantinib plus ADT has promising clinical activity in HNMPCa. CAF profiles and tissue markers suggest candidate prognostic and predictive markers of cabozantinib benefit and provide insights for rational therapy combinations.
Clinical • P2 data • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2RA (Interleukin 2 receptor, alpha)
|
FGFR1 expression
|
Cabometyx (cabozantinib tablet)
1year
DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway. (PubMed, J Endocrinol Invest)
Collectively, the present study demonstrated that DPP4 gene silencing inhibits PTC cell proliferation and EMT and promotes cell apoptosis via suppression of the MAPK pathway, thus highlighting a possible regulatory pathway in PTC progression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • FGFR1 (Fibroblast growth factor receptor 1) • CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
CDH1 expression • FGFR1 expression • BAX expression • HIF1A expression
|
Januvia (sitagliptin)
1year
Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. (PubMed, Life Sci)
These data collectively provided evidence that FGFR1 overexpression could be a potential cause of lenvatinib resistance and Oxysophocarpine could be an ideal combined therapy with lenvatinib in HCC treatment.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 overexpression • FGFR1 expression
|
lenvatinib
1year
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. (PubMed, EBioMedicine)
Our data show that the determination of the expression of FGFR1 or FGFR4 alone is not sufficient to predict anti-FGFR therapy efficacy; complementary determination of N-cadherin expression may further optimise patient selection for this therapeutic strategy.
Clinical • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR1 amplification • CDH1 expression • FGFR1 expression • FGFR4 expression
1year
[VIRTUAL] RNA-Based Gene Alteration and Expression Analysis in Sq-NSCLC with known FGFR1 Amplification and Protein Expression Status (IASLC-WCLC 2020)
The limited size of the study group, necessitates further research to confirm current observations. The research was co-financed by the NCBR and CelonPharmaS.A
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • NRG1 (Neuregulin 1)
|
NTRK1 fusion • NTRK3 fusion • FGFR1 amplification • FGFR2 fusion • ROS1 fusion • BRAF fusion • NRG1 fusion • FGFR1 expression • FGFR1 fusion • KIT fusion
1year
SSH3 promotes malignant progression of HCC by activating FGF1-mediated FGF/FGFR pathway. (PubMed, Eur Rev Med Pharmacol Sci)
In summary, SSH3 is capable of accelerating the malignant progression of HCC by activating FGF1-mediated FGF/FGFR pathway, thus becoming a new molecular target for HCC therapy.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 expression
1year
ROGABREAST: Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (clinicaltrials.gov)
P1, N=19, Recruiting, Fundacion CRIS de Investigación para Vencer el Cáncer | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
HER-2 negative • FGFR1 expression
|
Ibrance (palbociclib) • fulvestrant • rogaratinib (BAY 1163877)
1year
Prognostic significance of stem cell/ epithelial-mesenchymal transition markers in periampullary/pancreatic cancers: FGFR1 is a promising prognostic marker. (PubMed, BMC Cancer)
In addition to other clinicopathologic parameters, severe fibrosis was related to frequent tumor recurrence, and high FGFR1 expression was associated with better overall survival. Histologic changes such as extensive fibrosis need to be investigated further in relation to EMT of PACs.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • POU5F1 (POU Class 5 Homeobox 1) • CDX-2
|
FGFR1 expression
1year
Identification of Genomic Alterations of Perineural Invasion in Patients with Stage II Colorectal Cancer. (PubMed, Onco Targets Ther)
GO and pathway analysis revealed some genes enriched in specific pathways. These involved genomic changes in the PNI of stage II CRC may be useful to reveal the mechanisms underlying PNI and provide candidate biomarkers.
Clinical • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • FLT1 (Fms-related tyrosine kinase 1)
|
FGFR1 expression
1year
Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells. (PubMed, Transl Lung Cancer Res)
These cells were subsequently treated with increasing doses of the MET-TKIs capmatinib or crizotinib in combination with erlotinib to establish resistance. EMT is common in the development of sequential EGFR-TKI and MET-TKI resistance in NSCLC cells. Our findings contribute to the evidence of EMT as a common TKI resistance mechanism.
Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
EGFR mutation • MET amplification • MET mutation • CDH1 expression • FGFR1 expression • VIM expression • ZEB1 expression
|
Xalkori (crizotinib) • erlotinib • Tabrecta (capmatinib)
1year
Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. (PubMed, J Cell Mol Med)
Mechanism studies revealed that Sophoridine decreased ETS-1 expression to down-regulate VEGFR2 expression along with downstream RAS/MEK/ERK axis in LR HCC cells. Hence, our study revealed that up-regulated VEGFR2 expression could be a predicator of the resistance of lenvatinib treatment against HCC and provided a potential candidate to restore the sensitivity of lenvatinib for HCC treatment.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4) • ETS1 (ETS Proto-Oncogene 1)
|
FGFR1 expression • KDR expression • ETS1 expression • FLT1 expression
|
lenvatinib
1year
Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas. (PubMed, Neuropathology)
Finally, EGFL7 expression was not associated with overall or event-free survival of PA patients. Our findings point to EGFL7 expression as a novel candidate prognostic marker in PA, which should be further investigated.
Journal
|
BRAF (B-raf proto-oncogene) • FGFR1 (Fibroblast growth factor receptor 1) • MTAP (Methylthioadenosine Phosphorylase) • KIAA1549
|
BRAF mutation • FGFR1 mutation • KIAA1549-BRAF fusion • BRAF fusion • FGFR1 expression • FGFR1 fusion
1year
Anti-Cancer Effect of Cordycepin on FGF9-Induced Testicular Tumorigenesis. (PubMed, Int J Mol Sci)
Furthermore, cordycepin decreased FGF9-induced FGFR1-4 protein expressions in vitro and in vivo. In summary, cordycepin inhibited FGF9-induced testicular tumor growth by suppressing the ERK1/2, Rb/E2F1, cell cycle pathways, and the expressions of FGFR1-4 proteins, suggesting that cordycepin can be used as a novel anticancer drug for testicular cancers.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • E2F1 (E2F transcription factor 1)
|
FGFR1 expression
|
cordycepin (OVI-123)
1year
Ribociclib enhances Infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma. (PubMed, Liver Int)
Our findings demonstrate that the combined inhibition of FGFR/CDK4/6 pathways is highly effective in providing long-lasting tumour growth inhibition and cell differentiation and reducing drug resistance. Therefore, further clinical investigations in patients with FGFR1-3-dependant HCC are warranted.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CDK1 (Cyclin-dependent kinase 1)
|
FGFR1 expression
|
Kisqali (ribociclib) • Truseltiq (infigratinib)
1year
[VIRTUAL] The Altered Functional Status of Bone Marrow Stromal Progenitor Cells in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement Does Not Recover Many Years after Treatment (ASH 2020)
We aimed to compare functional properties of MSCs from the BM of patients in the onset of the disease, one month after treatment and more than 5 years in complete remission after treatment (R-CHOP or R-mNHL-BFM-90)...The work were supported by the Russian Foundation for Basic Research, Project No. 17-04-00170.
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • SPP1 (Secreted Phosphoprotein 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ICAM1 (Intercellular adhesion molecule 1) • SOX9 (SRY-Box Transcription Factor 9) • FGF2 (Fibroblast Growth Factor 2) • MMP2 (Matrix metallopeptidase 2) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • ENG (Endoglin) • MCAM
|
FGFR1 expression
|
Rituxan (rituximab)
1year
Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer. (PubMed, Oncogene)
Overall, our studies indicate that NRPs facilitate aberrant growth factor signaling during EMT-associated drug resistance and metastasis. Pharmacological combination of epigenetic modulators with FGFR-targeted kinase inhibitors may provide improved outcomes for breast cancer patients with drug-resistant metastatic disease.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • NRP1 (Neuropilin 1)
|
HER-2 amplification • HER-2 expression • FGFR1 expression
1year
Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. (PubMed, Cancers (Basel))
We provide evidence that the FGFR pathway has therapeutic potential for a subset of DDLPS and that an FGFR1/FGFR4 expression might constitute a powerful biomarker to select patients for FGFR inhibitor clinical trials. In addition, we show that combining erdafitinib with RG7388 is a promising strategy for patients with DDLPS that deserves further investigation in the clinical setting.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • MDM2 (E3 ubiquitin protein ligase) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR1 expression • FGFR expression • FGFR4 expression
|
Balversa (erdafitinib) • idasanutlin (RO5503781)
1year
ROGABREAST: Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (clinicaltrials.gov)
P1, N=19, Not yet recruiting, Fundacion CRIS de Investigación para Vencer el Cáncer | Trial completion date: Oct 2022 --> Apr 2023 | Initiation date: Oct 2020 --> Jan 2021 | Trial primary completion date: Oct 2022 --> Apr 2023
Clinical • Trial completion date • Trial initiation date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
HER-2 negative • FGFR1 expression
|
Ibrance (palbociclib) • fulvestrant • rogaratinib (BAY 1163877)
1year
Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance. (PubMed, Mol Med Rep)
Moreover, ST6Gal‑I overexpression cells had strong resistance to paclitaxel, as demonstrated by low growth inhibition rate and cell apoptosis level. In addition, ST6Gal‑I overexpression attenuated the effect of Adriamycin on cancer cells. Collectively, these results suggested that FGFR1 sialylation plays an important role in cell migration and drug chemoresistance in ovarian cancer cells.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 expression
|
paclitaxel • doxorubicin hydrochloride
1year
FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1. (PubMed, Cancers (Basel))
Resulting conjugate shows high and specific cytotoxicity towards FGFR1-positive cells, i.e., squamous cell lung carcinoma NCI-H520, while remaining non-toxic for FGFR1-negative cells. Such peptibody-drug conjugate can serve as a basis for development of therapy for tumors with overexpressed or malfunctioning FGFRs.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR1 expression • FGFR1 fusion
1year
Expression of fibroblast growth factor receptor like 1 protein in oral squamous cell carcinoma and its influence on tumor cell proliferation and migration (PubMed, Hua Xi Kou Qiang Yi Xue Za Zhi)
FGFRL1 expression in the OSCC tissues was significantly higher than that in the adjacent nontumor tissues. FGFRL1 expression in the OSCC cells was significantly higher than that in the HOK cells, and FGFRL1 had no effect on cell proliferation but promoted tumor cell migration and EMT.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CDH1 (Cadherin 1) • VIM (Vimentin)
|
CDH1 expression • FGFR1 expression • VIM expression
1year
MicroRNA-296 functions as a tumor suppressor in breast cancer by targeting FGFR1 and regulating the Wnt/β-catenin signaling pathway. (PubMed, Eur Rev Med Pharmacol Sci)
All these findings indicated that miR-296 exerted anti-BC functions, providing novel therapeutic strategies in BC treatment.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 expression
over1year
The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells. (PubMed, Eur J Pharmacol)
In this study, we tested the anti-leukemic activity of histone deacetylase inhibitor Belinostat (PXD101) and histone methyltransferase inhibitor 3-Deazaneplanocin A combined with all-trans retinoic acid in APL cells NB4, promyelocytes resembling HL-60 cells and APL patients' cells...In addition, effect of epigenetic treatment on protein expression of aforementioned signaling pathways was confirmed with mass spectrometry analysis. Taken together, these results provide supplementary insights into molecular changes that occur during epigenetic therapy application in in vitro promyelocytic leukemia cell model.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FLT4 (Fms-related tyrosine kinase 4) • TGFB1 (Transforming Growth Factor Beta 1) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR1 expression
|
Beleodaq (belinostat)
over1year
Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. (PubMed, Lung Cancer)
High CD31 was an independent poor prognostic factor and high PDGF-CC expression was associated with poor survival in MM. Abrogating these pathways may have prognostic implications.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
FGFR1 expression • CD31 expression
|
Avastin (bevacizumab) • nintedanib
over1year
The Relationship between Leptin, the Leptin Receptor and FGFR1 in Primary Human Breast Tumors. (PubMed, Cells)
These results demonstrate how elevated sera FGF2 and leptin in obese patients may promote cancer progression in tumors that express elevated FGFR1 and LepR through Jak2 signaling. Therefore, Jak2 is a potential therapeutic target for FGFR1 amplified breast cancer, especially in the context of obesity.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR1 amplification • FGFR1 expression
over1year
Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR-326/FGFR1 axis. (PubMed, Thorac Cancer)
Circ_0000518 facilitated BC development via regulation of the miR-326/FGFR1 axis, suggesting that circ_0000518 might be a promising target for BC treatment.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 overexpression • FGFR1 expression
over1year
[VIRTUAL] FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer (SABCS 2020)
MCF7 FGFR1(SP-)(NLS) cells were markedly less sensitive to fulvestrant compared to control cells...ChIP-Seq revealed that erdafitinib did not impair the FGFR1 genomic distribution... We have demonstrated a role for nuclear FGFR1 in transcriptional regulation in breast cancer. FGFR1-induced gene expression contributes to endocrine resistance and is not affected by FGFR TKIs. These findings provide a rationale for developing treatment strategies to inhibit nuclear FGFR1 in ER+/ FGFR1 -amplified breast cancer.
FGFR1 (Fibroblast growth factor receptor 1) • FOXA1 (Forkhead Box A1) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR1 amplification • FGFR1 expression
|
Balversa (erdafitinib) • fulvestrant
over1year
Analysis of Bone Tissue Condition in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement. (PubMed, Bull Exp Biol Med)
No direct relationship between changes in gene expression in multipotent mesenchymal stromal cells and osteoporosis markers was found. The presence of a tumor in the body affects the bone marrow stroma, but achievement of remission and compensatory mechanisms provide age-appropriate condition of the bone tissue.
Clinical • Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • SPP1 (Secreted Phosphoprotein 1) • SOX9 (SRY-Box Transcription Factor 9) • TGFB1 (Transforming Growth Factor Beta 1) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR1 expression
over1year
FGFR1 is critical for Rbl2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer. (PubMed, Cancer Res)
Additionally, FGFR1 activated phospholipase C gamma 1 (PLCG1) while chemical inhibition of PLCG1 suppressed SCLC growth, implicating PLCG1 as an effector of FGFR1 signaling in SCLC. Collectively, this study uncovers mechanisms underlying FGFR1-driven SCLC that involve RBL2 upstream and PLCG1 downstream, thus providing potential biomarkers for anti-FGFR1 therapy.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 amplification • FGFR1 expression
over1year
Journal • Polymerase Chain Reaction
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • MLH1 (MutL homolog 1) • FGF (Fibroblast Growth Factor)
|
KRAS mutation • BRAF mutation • FGFR1 amplification • FGFR1 expression • BRAF amplification
over1year
FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer. (PubMed, Clin Cancer Res)
Collectively, these findings suggest that while FGFR1 amplification confers broad resistance to ER, PI3K, and CDK4/6 inhibitors, TORC1 inhibitors might have a unique therapeutic role in the treatment of patients with ER+/FGFR1+ MBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • FGFR1 (Fibroblast growth factor receptor 1)
|
TP53 mutation • HR positive • ER positive • HER-2 amplification • FGFR1 amplification • FGFR1 expression
|
Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • fulvestrant
over1year
Circ_0015756 Aggravates Hepatocellular Carcinoma Development by Regulating FGFR1 via Sponging miR-610. (PubMed, Cancer Manag Res)
Circ_0015756 could regulate FGFR1 expression by targeting miR-610. Circ_0015756 played its tumorigenic properties in HCC by activating FGFR1 via sponging miR-610, and circ_0015756 was expected to be a vital indicator in HCC diagnosis and treatment.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 overexpression • FGFR1 expression
over1year
Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway. (PubMed, Cancer Res)
In tumor xenografts in mice, treatment with either BGJ398 or trametinib enhanced response to AZD9291 and improved survival. These results suggest that hypoxia is a driving force for acquired resistance to EGFR TKIs through increased expression of FGFR1. The combination of EGFR TKI and FGFR1 or MEK inhibitors may offer an attractive therapeutic strategy for NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
EGFR mutation • EGFR T790M • EGFR expression • FGFR1 expression • EGFR H1975 • EGFR mutation + EGFR T790M • ZEB1 expression
|
Mekinist (trametinib) • Tagrisso (osimertinib) • Truseltiq (infigratinib)
over1year
CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer. (PubMed, Clin Transl Oncol)
Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CCND1 (Cyclin D1)
|
HR positive • FGFR1 amplification • CCND1 amplification • CCND1 expression • FGFR1 expression
|
tamoxifen
over1year
[VIRTUAL] Circulating Tumor Cells Identified in Early-stage Breast Cancer Patients Using Fluorescence in Situ Hybridization Can Predict Therapy Resistance (SSO 2020)
FISH-CTCs found in patients on anti-estrogen therapy represent the best and earliest opportunity to evaluate molecular mechanisms of resistance. The molecular characterization of these cells may allow the addition of targeted secondary therapies to decrease clinical recurrence.
Clinical • Circulating Tumor Cells
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • FGFR1 (Fibroblast growth factor receptor 1)
|
HER-2 expression • FGFR1 expression
over1year
Overlapped differentially expressed genes between acute lymphoblastic leukemia and chronic lymphocytic leukemia revealed potential key genes and pathways involved in leukemia. (PubMed, J Cell Biochem)
The expression levels of 10 genes (SCML4, TNF-α, CD1C, FGFR1, MYO7B, DUSP1, PAP1GAP, MAN1C1, SLFN5, and CD8A) among the 26 genes were further confirmed by experiments, which was consistent with the results obtained by analyzing the RNA-seq data. The current study contributes to better understanding the pathophysiology of leukemia and unearthing novel potential prognostic markers and therapeutic targets of leukemia.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CD19 (CD19 Molecule)
|
FGFR1 expression
over1year
Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement. (PubMed, Mod Pathol)
The mutual exclusivity of ACVR2A rearrangements observed in synovial chondromatosis and FGFR1/2 in soft tissue chondromas suggests these represent separate entities. There have been no reports of malignant soft tissue chondromas, therefore differentiating these lesions will potentially alter clinical management by allowing soft tissue chondromas to be managed more conservatively.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor)
|
FGFR2 fusion • FGFR1 expression • FGFR1 fusion
over1year
Circ_0000885 Enhances Osteosarcoma Progression by Increasing FGFR1 Expression via Sponging MiR-1294. (PubMed, Cancer Manag Res)
In addition, circ_0000885 knockdown reduced OS tumor growth via regulating the FGFR1 expression by sponging miR-1294 in vivo. Circ_0000885 played an active role in OS progression, indicating that it might be a potential target for OS therapy.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
over1year
Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma. (PubMed, J Comput Assist Tomogr)
The CT radiomic features demonstrate correlations with FGFR1 status in HNSCC and should be further investigated for their potential to predict FGFR1 status.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • EPHA2 (EPH receptor A2) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
over1year
[VIRTUAL] Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience (ESMO 2020)
P=N/A | "Morgan Private Bank Clinical Oncology Research Grant, the National Cancer Institute grant P30 P30-CA023100 (R.K.), the Israeli Science Foundation grant 1188/16 (E.R.), Instituto Salud Carlos III—Programa Rio Hortega Contract grant CM15/00255 (I.B.), the Canadian Institutes for Health Research (grant MOP-142281 to W.H.M.) and the Canadian Cancer Society (grant 703811 to W.H.M.). Clinical trial identification: NCT01856296."
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR2 amplification • FGFR1 overexpression • PIK3CA amplification • FGFR2 overexpression • FGFR1 expression • PIK3CA expression • PIK3CA overexpression
|
FoundationOne® CDx
over1year
[VIRTUAL] Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SqCLC) targeted therapy (ESMO 2020)
Conclusions Multiplexed analysis of FGFR1 aberrations may contribute to broader patient population eligible for FGFR inhibitor therapy, which may increase its overall clinical feasibility and potential therapeutic benefits. Legal entity responsible for the study: Celon Pharma S.A. Funding: Celon Pharma S.A. & NCBR grant.
FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor)
|
FGFR1 amplification • FGFR1 expression • FGFR1 fusion
over1year
ROGABREAST: Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (clinicaltrials.gov)
P1; N=19; Not yet recruiting; Sponsor:Fundacion CRIS de Investigación para Vencer el Cáncer
New P1 trial • Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
HER-2 negative • FGFR1 expression
|
Ibrance (palbociclib) • fulvestrant • rogaratinib (BAY 1163877)
over1year
Clinical • Real-World Evidence
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 mutation • FGFR2 fusion • FGFR3 fusion • FGFR1 expression • FGFR1 fusion
over1year
circITGA7 Functions as an Oncogene by Sponging miR-198 and Upregulating FGFR1 Expression in Thyroid Cancer. (PubMed, Biomed Res Int)
Mechanistically, we found that circITGA7 acts as miR-198 competitive endogenous RNA (ceRNA) to regulate FGFR1 expression. In summary, circRNA circITGA7 may play a regulatory role in TC and may be a potential marker for TC diagnosis or progression.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
over1year
TIAM1 Upregulation Confers NVP-BEZ235 Resistance to Breast Cancer Cells Through FGFR/STAT3 Pathway. (PubMed, Biochem Genet)
Importantly, FGFR inhibitor AZD4547 decreased the IC50 of NVP-BEZ235, which suggested that FGFR downregulation reduced the NVP-BEZ235 resistance to breast cancer cells. In summary, our present study revealed that TIAM1 conferred NVP-BEZ235 resistance to breast cancer cells via activating FGFR/STAT3 pathway.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 expression
|
dactolisib (RTB101) • ABSK091
over1year
[VIRTUAL] Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression – NGS pilot study. (ERS 2020)
We revealed pathogenic variants in major cell signaling pathways, some associated with increased FGFR3 and MET expression.Yet, the limited size of the study group, necessitates further research to confirm current observations. The research was co-financed by the NCBR and Celon Pharma SA
Clinical • Next-generation sequencing
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR3 (Fibroblast growth factor receptor 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR1 (Fibroblast growth factor receptor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
NTRK2 fusion • FGFR3 fusion • MET expression • FGFR1 expression • NTRK expression
over1year
mRNA Expression of FGFR1 as Potential Marker for Predicting Prognosis of Surgical Resection of Small Cell Lung Cancer may be better than Protein Expression and Gene Amplification. (PubMed, J Cancer)
There was a distinct trend for mRNA level and poor prognosis, including recurrence-free survival (RFS) (p = 0.07) and overall survival (OS) (p= 0.08), but they did not reach statistical significance. As novel FGFR1-targeted therapies are developed, FISH, IHC, especially mRNA were detected, which should be considered as biomarkers of FGFR1 pathway dysregulation in SCLC.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 amplification • FGFR1 mutation • FGFR1 expression
over1year
Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer. (PubMed, Gastric Cancer)
We elucidated the molecular mechanisms underlying primary resistance to FGFR1 inhibitors in GC, and revealed that the inhibition of FGFR1 and TAK1 signaling could present a potential novel therapeutic strategy for FGFR1 inhibitor-resistant GC patients.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
|
ABSK091
over1year
Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors. (PubMed, Biomed Res Int)
High positive FGFR1 or 3 expression ratios were predicted in cholangiocarcinoma (58%), followed by bladder cancer (42%), endometrial carcinoma (35%), and ovarian cancer (34%). FGFR expression was a promising predictive biomarker for FGFR inhibition response in clinical trials, and different combinations of FGFR genes should be used in screening for patients in certain tumor types.
Clinical • Journal • Pan Tumor
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR mutation • FGFR1 expression • FGFR expression
over1year
[VIRTUAL] The relationship between FGFR1 and mevalonate in adiposity-associated cancer: Implications of statins for chemoprevention (SID 2020)
Using a screen to identify agents that block FGFR1-stimulated transformation, we identified fluvastatin, a HMG-CoA Reductase (HMG-CR) inhibitor, as a potential chemopreventive agent...Moreover, analysis of gene-sequenced melanomas from the Cancer Genome Atlas (TCGA) database shows a significant correlation between FGFR1 gene copy number and increased mevalonate gene copy number (p=0.00122). Together, our data implicate the VAT-FGFR1-Mevalonate pathway and its downstream mediators, such as Ras, in malignant transformation, and suggest that they may serve as targets for cancer prevention in the context of excess adiposity.
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation • FGFR1 expression
|
fluvastatin
over1year
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. (PubMed, Lancet Oncol)
Rogaratinib was well tolerated and clinically active against several types of cancer. Selection by FGFR mRNA expression could be a useful additional biomarker to identify a broader patient population who could be eligible for FGFR inhibitor treatment.
Clinical • P1 data • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
|
rogaratinib (BAY 1163877)
over1year
Sulfated syndecan 1 is critical to preventing cellular senescence by modulating fibroblast growth factor receptor endocytosis. (PubMed, FASEB J)
Finally, the replicatively and prematurely senescent cells were characterized by decreases of SDC1 expression and FGFR1 internalization, and an increase in FGFR1-AKT-p53-p21 signaling. Together, our results demonstrate that properly sulfated SDC1 plays a critical role in preventing cellular senescence through the regulation of FGFR1 endocytosis.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
over1year
DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis. (PubMed, J Biol Chem)
These findings provide evidence that MYC activates MYB by up-regulating DNMT1, which silences miR-150-5p and promotes SCLL progression. We propose that the inclusion of mebendazole in a combination therapy with FGFR1 inhibitors may be a valuable option to manage SCLL.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • DNMT1 (DNA methyltransferase 1) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
over1year
Screening and Identification of Differentially Expressed Genes Expressed among Left and Right Colon Adenocarcinoma. (PubMed, Biomed Res Int)
CDKN2A expression was significantly different between LCOAD and RCOAD and was closely related to the prognosis of COAD. It is of great value for further understanding of the pathogenesis of LCOAD and RCOAD.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • IGF1R (Insulin-like growth factor 1 receptor)
|
FGFR1 expression • CDKN2A expression
over1year
[VIRTUAL] Tyrosine kinase inhibition of fibroblast growth factor receptor 1 in advanced prostate cancer (AACR-II 2020)
These findings indicate that the presence of specific FGFR1 variants should be considered for treatment selection in advanced PCa. The results also suggest that FGFR1-pMAPK pathway blockade by JNJ-42756493 should be further studied as a strategy to guide the development of therapies to hinder PCa progression.
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
|
Balversa (erdafitinib)
over1year
[VIRTUAL] Neuropilin 1 is required for fibroblast growth factor receptor-mediated tumor progression (AACR-II 2020)
Overall our studies indicate that Nrp1 facilitates aberrant FGFR signaling during EMT-associated drug resistance and metastasis. Pharmacological targeting of these key factors may provide improved outcomes for late stage breast cancer patients.
HER-2 (Human epidermal growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor) • NRP1 (Neuropilin 1)
|
HER-2 amplification • FGFR1 expression • NRP1 elevation
over1year
[VIRTUAL] FGFR1 associates with gene promoters and regulates transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance (AACR-II 2020)
These findings support a prominent role for FGFR1 in the transcriptional machinery of breast cancer cells. Whether this transcriptional action is causal to antiestrogen resistance in ER+/FGFR1-amplified breast cancer is currently under investigation.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • FGFR1 (Fibroblast growth factor receptor 1) • FOXA1 (Forkhead Box A1)
|
ER positive • FGFR1 amplification • FGFR1 expression
|
letrozole
over1year
[VIRTUAL] Hypoxia induces EGFR inhibitor resistance in lung cancer cells by upregulation of fibroblast growth factor receptor 1 (FGFR1) via MAPK pathway (AACR-II 2020)
In our previous study, we showed that long-term, moderate hypoxia promotes resistance to the EGFR TKI, gefitinib, in the NSCLC cell line, HCC827, which harbors an activating EGFR mutation...In vivo in tumor xenografts in mice, BGJ398 treatment or trametinib treatment suppresses tumor growth and enhances AZD9291 response. These results suggest that hypoxia is a driving force for acquired resistance to EGFR TKIs through increased FGFR1 expression and coordination of EMT in NSCLC. The combination of EGFR TKIs and FGFR1 or MEK inhibitors may offer an attractive therapeutic strategy for NSCLCs.
EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CDH1 (Cadherin 1) • FGF (Fibroblast Growth Factor) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
EGFR mutation • EGFR T790M • CDH1 expression • FGFR1 expression • EGFR H1975 • ZEB1 expression
|
Mekinist (trametinib) • Tagrisso (osimertinib) • gefitinib • Truseltiq (infigratinib)
over1year
[VIRTUAL] Biochemical characterization of FGFR2-PPHLN1 and BCR-FGFR1, drivers of epithelial and hematological malignancies (AACR-II 2020)
Preliminary data suggests that transformed cells expressing either FGFR2-PPHLN1, or kinase activated FGFR2(N549K)-PPHLN1, may be sensitive to treatment with FGFR inhibitor TAS-120, suggesting that TAS-120 treatment could be beneficial for patients with FGFR2-PPHLN1 driven ICC. Transformed cells expressing BCR-FGFR1 are sensitive to the Hsp90 inhibitor, Ganetespib, and also respond to combined treatment with Ganetespib and FGFR inhibitor BGJ398, suggesting novel clinical treatment options for patients positive for this fusion. Collectively, we show that the tyrosine kinase activity provided by FGFR2 or FGFR1, respectively is required for the biological activity of these fusion proteins, and we establish novel treatment options for patients with FGFR2-PPHLN1 or BCR-FGFR1 driven malignancies.
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor)
|
FGFR2 mutation • FGFR2 fusion • FGFR2 N549K • FGFR mutation • FGFR1 expression • FGFR1 fusion
|
Truseltiq (infigratinib) • futibatinib (TAS 120) • ganetespib (ADX-1612)
over1year
[VIRTUAL] Regulation of osteosarcoma cell metastasis by FGFR and mTOR signaling (AACR-II 2020)
Orthotopic injection of OS cells demonstrated that small molecule inhibition of both FGFR1 and mTOR signaling (AZD4547 and AZD8055, respectively), showed greater inhibition of size and diameter of lung metastatic nodules than each inhibitor alone. The mechanisms are not yet known but are independent of the primary tumour.Taken together, our data suggest that combinatorial treatment significantly decreased lung metastasis of OS cells from primary xenografts. Ongoing analysis of activated FGFR and mTOR pathways in patient-derived tissue microarrays will enable patient stratification that will be useful in the clinical setting to exploit this as a potential anti-metastatic therapy in OS.
FGFR (Fibroblast Growth Factor Receptor) • CASP3 (Caspase 3)
|
FGFR1 expression
|
ABSK091 • AZD8055
over1year
Comprehensive Analysis of Fibroblast Growth Factor Receptor (FGFR) Family Genes in Breast Cancer by Integrating Online Databases and Bioinformatics. (PubMed, Med Sci Monit)
CONCLUSIONS Our study comprehensively analyzed the prognostic values of FGFR1-4 expression in BC and proposed FGFR2 might serve as a promising biomarker. However, the underlying mechanisms remain to be elucidated.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD44 • FGF (Fibroblast Growth Factor) • MMP9 (Matrix metallopeptidase 9)
|
FGFR2 overexpression • FGFR1 expression
over1year
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. (PubMed, J Transl Med)
The high incidence of dissimilar target expression status in clinical samples from primary vs. recurrent GBM suggests clinically relevant heterogeneity along the course of disease. Molecular target expression, as determined at primary diagnosis, may not necessarily present rational treatment clues for the clinical care of recurrent GBM. Further studies need to analyze the therapeutic impact of longitudinal heterogeneity in GBM.
Journal
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • KDR (Kinase insert domain receptor) • FGFR (Fibroblast Growth Factor Receptor)
|
EGFR expression • FGFR1 expression
|
temozolomide
over1year
[VIRTUAL] Receptor tyrosine kinases and growth factors expression in tumor thrombus cells in patients with renal cell carcinoma (RCC). (ASCO 2020)
RCC invasion into veins is accompanied by a decrease in expression of RTKs and GFs. Further studies are needed to understand the biological significance. Research Funding: None
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • KDR (Kinase insert domain receptor) • VEGFA (Vascular endothelial growth factor A) • FLT1 (Fms-related tyrosine kinase 1) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression • KDR expression • FLT1 expression
over1year
[VIRTUAL] FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. (ASCO 2020)
This data suggests that while FGFR1-3 genes are overall expressed in CRC and lung, some cases may have significantly high expression of FGFR1-3 and perhaps these cases should be singled out for treatment with FGFR inhibitors. Furthermore, NGS testing for mutations significantly more efficient and can detect significant number of mutations that can be missed if PCR-based testing is used. NGS testing of DNA and RNA is the most appropriate testing for abnormalities in FGFR1-4.
Next-generation sequencing
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FGF (Fibroblast Growth Factor)
|
FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion • FGFR1 expression • FGFR1 fusion • FGFR3 expression • FGFR expression • FGFR4 expression
over1year
[VIRTUAL] The relationship between leptin, leptin receptor, and FGFR1 in primary human breast tumors. (ASCO 2020)
Taken together, these results suggest that elevated sera FGF2 and leptin in obese patients may promote breast tumorigenesis in tumors that express elevated FGFR1 and LepR and that Jak2 inhibitors may be a novel therapeutic option for adiposity-driven breast cancers. Future work will examine the relationship between FGFR1/leptin receptor expression and survival and how these relationships are influenced by BMI status. Research Funding: Endowment Awards from Michigan State University
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression
over1year
Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma. (PubMed, BMC Cancer)
FGFR1 amplification may serve as an independent prognostic factor for disease-free survival in hypopharyngeal and laryngeal SCC. Aberrant FGFR signaling caused by FGFR1 gene amplification or protein overexpression may play a crucial role in the malignant evolution and progression of hypopharyngeal and laryngeal SCC, and offer novel therapeutic opportunities in patients with hypopharyngeal and laryngeal SCC that usually lack specific therapeutic targets.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 amplification • FGFR1 expression
almost2years
Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas. (PubMed, Int J Radiat Oncol Biol Phys)
These findings suggest that AZD4547 can augment the response of radiation in FGFR-expressing HNSCC in vivo model systems. FGFR1 and FGFR2 may prove worthy targets for radiosensitization in HNSCC clinical investigations.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR1 expression • FGFR expression
|
ABSK091
almost2years
Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer. (PubMed, Cells)
Furthermore, FGFR1 and PARP expression was upregulated in FGFR1 inhibitor (dasatinib)-resistant PDAC cell lines SU8686, MiaPaCa2, and PANC-1 compared with that in sensitive cell lines Panc0403, Panc0504, Panc1005, and SUIT-2. In conclusion, FGFR1 inhibitor-resistant PDAC cells exhibited sensitivity to PD173074 after olaparib-mediated loss of PARP signaling. The present FGFR1/PARP-mediated synthetic lethality proof-of-concept study provided preclinical evidence of the feasibility and therapeutic efficacy of combinatorial FGFR1/PARP1 inhibition in human PDAC cell lines.
Clinical • Journal • PARP Biomarker
|
FGFR1 (Fibroblast growth factor receptor 1) • BCL2L1 (BCL2-like 1) • RAD51 (RAD51 Homolog A) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
LDH-H • FGFR1 expression • PARP1 overexpression
|
Lynparza (olaparib) • dasatinib
almost2years
Mutational landscape and genetic signatures of cell-free DNA in tumour-induced osteomalacia. (PubMed, J Cell Mol Med)
The genetic signatures and corresponding change in expression of FGFR1 and FGF23 were further validated in PMT tissues from a test cohort of another three TIO patients. In summary, we reported the first study of the mutational landscape and genetic signatures of cfDNA in TIO/PMTs.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
almost2years
Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells. (PubMed, Lung Cancer)
From our findings concerning the cause-and-effect relationship in the genetic background of EGFR-mutated NSCLC cells, we conclude that an increase in ZEB1 expression is a driver of EMT resulting in concomitant increased FGFR1 expression, whereas an increase in FGFR1 expression is insufficient to drive concomitant EMT.
Journal
|
EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
EGFR mutation • EGFR expression • FGFR1 expression • CA9 expression • ZEB1 expression
almost2years
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. (PubMed, Elife)
This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor's assessment is that all the issues have been addressed (see decision letter).
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
almost2years
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor (FGFR) Inhibitor for Intrahepatic Cholangiocarcinoma. (PubMed, Am J Pathol)
We examined FGFR expression in CCA tumor specimens obtained from patients and CCA cell lines, and then determined the effects of the novel FGFR inhibitor, derazantinib (DZB; formally, ARQ 087), which is currently in clinical phase 2 trials for intrahepatic CCA...These correlated in vitro studies suggest that FGFR may play an important role in the pathogenesis and biology of CCA. Our findings support the notion that FGFR inhibitors, like DZB, should be further evaluated at the clinical stage as targeted therapy for CCA treatment.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
|
derazantinib (ARQ 087)
almost2years
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma. (PubMed, BMC Pulm Med)
PD-L1 expression in SCC was correlated with severity of emphysema in TC0, 1, 2 vs. TC3 and more frequent in none-mild emphysema than moderate-severe emphysema.
Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • FGFR1 (Fibroblast growth factor receptor 1)
|
PD-L1 expression • FGFR1 expression
almost2years
Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer. (PubMed, Cancer Med)
We believe that patient selection for FGFR1 inhibitors in clinical studies should be reconsidered. Neither FGFR1 amplification nor expression influences patient's prognosis.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 amplification • FGFR1 expression
almost2years
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 expression
|
gemcitabine
almost2years
PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma. (PubMed, Theranostics)
More importantly, addition of PI3K inhibitor to R-CHOP completely suppressed the tumor growth of R-CHO-resistant DLBCL cells, most likely by converting CSCs to chemo-sensitive differentiated cells. The PI3K/AKT/SOX2 axis plays a critical role in R-CHOP resistance development and the pro-differentiation therapy against CSCs proposed in this study warrants further study in clinical trials for the treatment of resistant DLBCL.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CD133 • CD34 (CD34 molecule) • CDK6 (Cyclin-dependent kinase 6) • SOX2
|
FGFR1 expression • CDK6 expression
|
Rituxan (rituximab)
almost2years
Ablation of low-molecular-weight FGF2 isoform accelerates murine osteoarthritis while loss of high-molecular-weight FGF2 isoforms offers protection. (PubMed, J Cell Physiol)
Moreover, Fgf2 OA cartilage exhibited increased FGF2, FGF23, and FGFR1 expression, whereas Fgf2 cartilage had increased levels of FGFR3, which promotes anabolism in cartilage. These results demonstrate that loss of LMW FGF2 results in catabolic activity in joint cartilage, whereas absence of HMW FGF2 with only the presence of LMW FGF2 offers protection from OA.
Preclinical • Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • IGF1 (Insulin-like growth factor 1) • BAX (BCL2-associated X protein) • SOX2
|
FGFR1 expression
almost2years
TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. (PubMed, PLoS One)
The germline TP53 codon 72 polymorphism was associated with mutations of FGFR3 or RAS and expression of FGFR1 and FGFR3 in NMIBC. These findings provide new insight into the molecular mechanisms underlying the influence of the genetic background on carcinogenesis in bladder cancer.
Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR3 mutation • FGFR1 expression
almost2years
FGFR1-4 high mRNA expression (mRNAh) as predictive biomarker for FGFR inhibitors in breast cancer (BC) (TAT 2020)
In this exploratory study, total FGFR1-4 mRNAh is a predictive biomarker for FGFRinh (e.g. rogaratinib) but not for MTKI such as lucitanib in BC PDXs. MTKI efficacy does not rely on mRNAh levels of its targets in BC.
FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FLT1 (Fms-related tyrosine kinase 1)
|
FGFR2 mutation • FGFR1 expression • FLT1 expression
|
rogaratinib (BAY 1163877) • lucitanib (E 3810)
2years
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression (clinicaltrials.gov)
P2, N=0, Withdrawn, Dana-Farber Cancer Institute, N=33 --> 0 | Trial completion date: Jun 2021 --> Nov 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Nov 2019
Clinical • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
ALB (Albumin)
|
FGFR1 expression
|
rogaratinib (BAY 1163877)
over2years
Clinical • New P2 trial
|
ALB (Albumin)
|
FGFR1 expression
|
rogaratinib (BAY 1163877)